Autoimmune Hemolytic Anemia After Cyanocobalamin Replacement in a Patient With a Previous Diagnosis of Pernicious Anemia: A Case Report

ABSTRACT: Pernicious anemia (PA) is associated with other autoimmune diseases, such as hypothyroidism, type 1 diabetes mellitus (DM1), Addison's disease, and vitiligo. The association between PA and autoimmune hemolytic anemia (AIHA) is rare, with less than 30 cases reported in the literature....

Full description

Autores:
Mejía Buriticá, Leonardo
Zapata Álvarez, Jesús
Vergara Quintero, Lissette
Villegas Molina, Juan Pablo
Torres Hernández, José Domingo
Tipo de recurso:
Article of investigation
Fecha de publicación:
2020
Institución:
Universidad de Antioquia
Repositorio:
Repositorio UdeA
Idioma:
eng
OAI Identifier:
oai:bibliotecadigital.udea.edu.co:10495/42632
Acceso en línea:
https://hdl.handle.net/10495/42632
Palabra clave:
Anemia Hemolítica Autoinmune
Anemia, Hemolytic, Autoimmune
Prueba de Coombs
Coombs Test
Anemia Perniciosa
Anemia, Pernicious
Glucocorticoides
Glucocorticoids
https://id.nlm.nih.gov/mesh/D000744
https://id.nlm.nih.gov/mesh/D003298
https://id.nlm.nih.gov/mesh/D000752
https://id.nlm.nih.gov/mesh/D005938
Rights
openAccess
License
http://creativecommons.org/licenses/by/2.5/co/
Description
Summary:ABSTRACT: Pernicious anemia (PA) is associated with other autoimmune diseases, such as hypothyroidism, type 1 diabetes mellitus (DM1), Addison's disease, and vitiligo. The association between PA and autoimmune hemolytic anemia (AIHA) is rare, with less than 30 cases reported in the literature. In this paper, we report a case of a patient with a confirmed diagnosis of PA, who, six months after starting treatment with cyanocobalamin, presented with severe hemolysis with a positive direct antiglobulin test (DAT) for warm antibodies; the patient responded well to glucocorticoid treatment. AIHA in PA patients can be triggered by cyanocobalamin replacement due to the expression of membrane antigens by mature red blood cells entering into the peripheral circulation. This association should be considered because these patients, in addition to cyanocobalamin replacement, will require immunosuppressive treatment, usually with glucocorticoids.